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Substance use disorders (SUDs), whether active or in remission, are often encountered in patients with chronic
nonmalignant pain. Clinicians are challenged when managing chronic pain while facing substance abuse issues
during the course of chronic opioid therapy (COT). Further, the interrelated behavioral symptomatology of
addiction and chronic pain suggests that if one disorder is untreated, effective treatment of the other in not
possible. Incomplete understanding of the overlapping presentations of the two disorders, coupled with insufficient
management of both conditions, leads to undertreated pain and premature discharge of SUD patients from pain
treatment. In order to achieve pain relief and optimal functionality, both conditions need to be carefully managed.
This paper reviews the prevalence of SUDs in chronic pain patents; the overlapping presentation of the two
disorders; risk factors and stratification for addiction; identification of addiction in the chronic pain population; and
suggestions for treating patients with COT, with an emphasis on relapse prevention. With appropriate assessment
and treatment, COT for chronic pain patients with a history of SUD can be successful, leading to improved
functionality and quality of life.
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Treating chronic pain with chronic opioid therapy
(COT) in individuals with a history of a substance use
disorder (SUD), whether active or in remission, presents
a challenge to pain clinicians. This is, in part, due to
concerns about the patient relapsing to active substance
abuse in the course of COT, as analgesic treatment en-
ables and legitimizes drug use for patients with SUDs
[1-3]. In addition, clinicians may confuse “drug-seeking”
behaviors with addictive disease, resulting in poor treat-
ment outcomes such as premature discharge of patients
from pain care [4]. Misconceptions persist as chronic pain
patients with SUDs are often treated by clinicians who
have insufficient training in addiction, and evidence-based
clinical guidelines for managing pain while addressing
SUDs are lacking [2,5]. The goal of chronic pain treatment
in patients with SUDs is the same as that for patients
without SUDs: specifically, to maximize functionality
while providing pain relief. However, reluctance to* Correspondence: yc73@buffalo.edu
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distribution, and reproduction in any mediumprescribe opioids and poor understanding of the com-
plex relationship between pain and addiction too often
result in undertreated pain in this population [6].
A review of the literature reveals that no empirical
studies have been conducted to investigate the risks and
benefits associated with COT in chronic pain patients
with a history of SUD [7]. This paper reviews what is
known about the prevalence of SUDs in chronic pain
patents; links between pain and addiction; risk factors
and stratification for addiction and implications for
COT; and indicators of addiction in this population.
Suggestions for treating chronic pain in SUD patients
receiving COT are outlined with an emphasis on the role
of relapse prevention in successful outcomes.Prevalence of SUDs in chronic pain patients
In attempting to estimate the prevalence or presence
of SUD in chronic pain patients, terminology becomes
important (Table 1). It is increasingly understood that
SUD cannot be defined by physical dependence and
tolerance, as these are predictable physiologic conse-
quences of chronic opioid use. Reflecting this, in the
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Table 1 Definition of terminology
Terms Definitions
Misuse Taking a prescription for a reason or at a dose or frequency other than for which it was prescribed; this may or may not
reflect POUD*.
Use of a medication for nonmedical use, or for reasons other than prescribed. For example, altering dosing or sharing
medicines, which has harmful or potentially harmful consequences. It does not refer to use for mind-altering purposes [9].
Abuse Misuse with consequences. The use of a substance to modify or control mood or state of mind in a manner that is illegal
or harmful to oneself or others. Potentially harmful consequences include accidents or injuries, blackouts, legal problems,
and sexual behavior that increases the risk of human immunodeficiency virus infection [9].
Physical dependence A state of adaptation manifested by a drug class-specific withdrawal syndrome that can be produced by abrupt cessation,
rapid dose reduction, decreasing blood level of the drug, and/or administration of an antagonist [10].
Tolerance A state of adaptation in which exposure to a drug induces changes that result in a diminution of one or more opioid
effects over time [10].
Addiction A primary, chronic, neurobiologic disease with genetic, psychosocial, and environmental factors influencing its
development and manifestations. It is characterized by behaviors that include one or more of the following: impaired
control over drug use, compulsive use, continued use despite harm, and craving [10].
Pseudo-addiction An iatrogenic syndrome of “addiction-like” behaviors in which the patient seeks opioids to relieve pain—such as seeking
different doctors, self-adjusting the opioid dose, early refills of opioids, etc.—rather than to achieve pleasure or other
nonpain-related effect [11]. At times mistaken for true addiction, these behaviors tend to resolve and function improves
once analgesia is better addressed. Further defined as “behavioral changes in patients that seem similar to those in patients
with opioid dependence or addiction but are secondary to inadequate pain control” [12].
Therapeutic dependence Drug-seeking secondary to anxiety about having an adequate supply of medication [13].
Opioid-induced
hyperalgesia
A state of nociceptive sensitization caused by exposure to opioids. The condition is characterized by a paradoxical
response, whereby a patient receiving opioids for the treatment of pain could actually become more sensitive to certain
painful stimuli. The type of pain experienced might be the same as the underlying pain or might be different from the
original underlying pain [14,15].
Aberrant drug-related
behavior
Taking a controlled substance medication in a manner that is not prescribed; causes for this may include:
• lack of understanding about how to take the opioid appropriately
• external pressures, such as to give to another person for his or her pain
• chemical coping
• pseudoaddiction (see below), including:
– physical tolerance and resultant inadequate pain control
– opioid-resistant pain
– opioid-induced hyperalgesia
– progression of their pain generator or disease
• addiction or substance use disorder (such as POUD)
• diversion
A behavior outside the boundaries of the agreed-on treatment plan which is established as early as possible in the
doctor-patient relationship [16].
*POUD: prescription opioid use disorder.
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counted as criteria for the substance use and addictive
disorder diagnosis if a patient is taking an opioid anal-
gesic under medical supervision [8].
Albeit using imperfect indicators, it has been esti-
mated that the prevalence of opioid abuse in chronic
pain patients ranges between 20-24% across health-care
settings [17]. Using a survey approach and DSM-IV cri-
teria, Boscarino and colleagues [18] completed phone
interviews with a random sample of 705 chronic pain
patients receiving COT in primary care and specialty
pain treatment. They found that 26% of those reported
a current opioid use disorder and 36% had a life-timeopioid use disorder, findings that were replicated using
DSM-V criteria [19]. A systematic review of literature
synthesizing 21 studies published prior to February 2012
showed that the overall prevalence of current SUDs in
chronic pain patients ranges from 3% to 48% depending
on the population sampled [7]. The lifetime prevalence of
any SUD ranged from 16% to 74% in patients visiting the
emergency department, with those visiting for opioid refill
having the highest rate. Further, it has been reported that
3.3% to 11.5% of chronic pain patients with a history of
SUD may develop opioid addiction or abuse, whereas only
0.19% to 0.59% of those without a prior or current history
of SUD develop the same [20].
Table 2 Evidence of functional restoration [8]
• Physical capabilities
• Psychological intactness
• Satisfying family and social interactions
• Appropriate health-care utilization
• Appropriate medication use
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Chronic pain and addiction are best conceptualized as a
syndrome. In some individuals with addictive disease,
pain is identified as a factor contributing to their addic-
tion. It has been hypothesized that untreated pain may
be a risk factor for relapse for individuals with addiction
in remission [21]; however, it has also been suggested
that exposure to opioids in chronic pain patients with a
history of SUD puts them at risk for opioid abuse and/or
relapse [22].
Physiological and psychological aspects of active ad-
dictive disease can make pain more difficult to treat.
Chronic use of opioid drugs appears to affect the pro-
cessing of pain stimuli through sympathetic stimulation,
hypothalamic-pituitary-adrenal axis dysregulation, and
proinflammatory immune-system activation, resulting in
increased sensitivity to pain or decreased pain tolerance
[14,23]. These responses suggest that the presence of
both chronic pain and opioid addiction may result in a
reorganization of nociceptive pathways in the brain that
subsequently cause increased pain perception, or so-called
opioid-induced hyperalgesia.
Savage and Schofferman [24] described a “syndrome of
pain facilitation” occurring in patients with untreated
addiction and pain, such that the pain experience is
worsened by the presence of addiction. Individuals who
abuse alcohol, cocaine, opioids, or other drugs often
experience alternating withdrawal and intoxication due
to unstable blood levels of drug. Similarly, for indivi-
duals receiving opioids, withdrawal can activate the
sympathetic nervous system, with concomitant muscle
tension, irritability, and dysphoria, further contributing
to discomfort.
Mood, sleep, and personality disorders can aggravate
pain symptoms and are frequently comorbid in patients
with chronic pain [25-30]. The literature indicates that
chronic pain patients with untreated depression respond
poorly to pain treatment [31,32]. Due to functional limi-
tations, chronic pain patients may become isolated and
unable to engage in physical and social activities, which
further contribute to the severity of the chronic pain
experience [33,34]. Unable to fulfill work and domestic
roles, they are also likely to experience interpersonal
conflicts, financial difficulty, and poor social support,
all of which are detrimental to adequate chronic pain
management [35].
Similarly, mood disorders, including depression and
anxiety, are common sources of distress in patients with
SUD [36-38], which likewise diminish patient functiona-
lity [33]. The overall dysfunction associated with addic-
tion contributes to distress and disability. Further, pain
patients with active addition are unlikely to comply with
nonopioid pain treatment regimens, including physical
therapy and behavioral interventions. The signs andsequelae of untreated addiction thwart improvement
with COT.
Unresolved emotional and social distress coupled with
persistent pain may lead patients to self-medicate these
uncomfortable feeling states with opioids. When self-
medication becomes a coping mechanism, substance use
can progress to a disorder, or cause relapse in patients
with a history of SUD. In a recent study of 1334 patients
receiving COT for noncancer chronic pain, those with
moderate and severe depression were more likely to self-
medicate nonpain symptoms with prescription opioids
and to misuse their prescription opioid by self-increasing
doses than were those without depression [39].Risk factors and risk stratification for addiction in pain
patients receiving COT
Clinicians should conduct a comprehensive risk assess-
ment for opioid abuse or misuse when considering use
of COT. The assessment should include known risk
factors for addiction, including a personal or family his-
tory of substance abuse, childhood adverse events (eg,
physical or sexual abuse, childhood neglect), psychiatric
symptoms, and functional impairment (pain disability,
sleep disturbance). With respect to pain symptoms,
assessment in patients considered at risk for addictive
disease must include careful delineation of the noci-
ceptive and affective components of the pain syndrome;
identification of associated factors that perpetuate pain;
and identification of pain-related risk factors for opioid
abuse and relapse. Degree of functionality (Table 2) in the
presence of chronic pain is a critical assessment, as the
effectiveness of COT is evident in this domain.
Risk stratification approaches are indicated for selecting
chronic pain patients for COT, and those with a history of
SUD are considered at high risk for poor treatment re-
sponse [40]. Being a chronic disease, it is critical to ensure
that SUD’s continue to be addressed while treating chronic
pain. Gourlay, Heit, and Almahrezi [41] propose a 10-step
universal precaution approach as a minimum standard of
care for all chronic pain patients receiving COT (Table 3).
This model of universal precautions is framed within a
biopsychosocial approach and designed to reduce stigma,
improve outcomes, and decrease risks associated with
COT pain management for all patients [41], regardless of
SUD history.
Table 3 Ten steps of universal precautions
1. Make a diagnosis with appropriate differential.
2. Perform a psychological assessment, including risk of addictive
disorders.
3. Obtain informed consent.
4. Use a treatment agreement.
5. Conduct assessment of pain level and function before and after the
intervention.
6. Begin an appropriate trial of opioid therapy with or without
adjunctive medications and therapies.
7. Reassess pain score and level of function.
8. Regularly assess the 4 “As” of pain medication: Analgesia, Activity,
Adverse effects, and Aberrant behavior.
9. Periodically review pain diagnosis and co-occurring conditions,
including addictive disorders.
10. Document initial evaluation and follow visits.
Adopted from Gourlay DL et al [41].
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The risk factors for opioid abuse, misuse, or other aberrant
drug-related behaviors in chronic pain patients receiving
COT have been well-described, with a prior history of
opioid abuse being the best predictor for both current and
lifetime opioid use disorder in chronic pain patients
[18,42]. Other important but less consistent risk factors
for opioid abuse include pain-related functional limita-
tions/impairments (including sleep disturbances); current
cigarette smoking; a family history of substance abuse; a
history of a mood disorder (eg, current post-traumatic dis-
order or depression); history of child sexual abuse or child
neglect; involvement in the legal system; and significant
psychosocial stressors [43-45]. Demographic correlates of
opioid misuse in this patient population include age,
gender, ethnicity, and employment status. Previous studies
indicate that younger chronic pain patients (under age 65)
are at higher risk for opioid abuse [18,46]. With respect to
gender, women with chronic pain who reported more
emotional issues and affective distress were at increased
risk for opioid misuse, whereas men with legal problems
tended to predict misuse prescription opioids [47].
Boscarino and colleagues [18] found that the chance
of opioid abuse increases if a chronic pain patient has
multiple risk factors, such that the odds ratio (OR) of a
current opioid use disorder in chronic pain patients who
present with four predictors (age, depression, psychotropic
medication, and pain impairment) is 8.01. If the patient
also has a history of severe opioid dependence and abuse,
the risk of current opioid use disorder increased dramati-
cally (OR, 56.36).
Risk stratification and monitoring strategies
Atluri and colleagues [48] have suggested an algorithmic
approach to prevent opioid abuse in chronic pain treat-
ment by stratifying patients into high-, medium-, and low-risk groups using one of several validated screening tools
(Figure 1). These tools include subjective questionnaires,
eg, Screener and Opioid Assessment for Patients with Pain
(SOAPP) [49], Pain Medication Questionnaire (PMQ)
[50], and Prescription Drug Use Questionnaire Patient
Version (PUDQP) [51]); and objective tools, eg, Addiction
Behavior Checklist (ABC) [52], Diagnosis, Intractability,
Risk, Efficacy (DIRE) [53], and Current Opioid Misuse
Measure (COMM) [54].
Based on the stratification of risk, different approaches
are suggested. Individuals with a history of SUD are
categorized as high risk, thus, frequent monitoring of
medication use, urine drug testing (UDT) every three to
six months, and reviewing Prescription Monitoring
Program (PMP) reports every two to four months are
recommended. Although not uniformly supported in
the literature, these authors suggest that opioids should
be avoided or prescribed only in low doses; a >50 mg
morphine-equivalent dose should be used only rarely and
only in specialized settings.
Building on the universal precautions, management
can be tailored to the care for patients at risk for SUD.
For example, in addition to the general components
written in the opioid treatment agreement or contract,
the clinician should stipulate that participation in on-
going addiction treatment (eg, 12-step meetings, out-
patient treatment, or individual counseling/therapy) be
required for COT prescription. More frequent office
visits are required to better assess opioid use behaviors,
opioid efficacy, and signs of relapse. Clinicians should
prescribe opioids to these patients in smaller amounts,
without refills, and conduct pill counts at each visit. If
appropriate, a family member or a close friend can be
included in the treatment plan (for example, to dispense
medications).
Clinicians should collect urine samples more frequently
for mass spectrometry confirmatory toxicology screen
[55]. In a large prospective study of chronic pain patients
receiving COT (N= 500), Manchikanti and colleagues [56]
found significant reductions in overall illicit drug use with
adherence-monitoring procedures combined with random
UDT. Continued monitoring using UDT significantly de-
creased the incidence of illicit drug use over time [57]. It is
important to note that, although UDT is an objective
measure of the presence of drugs and their metabolites, it
is not a stand-alone indicator of adherence or addiction;
thus, the results should be openly discussed with patients
along with assessment of other indicators of relapse.
False-positive and false-negative results can occur with
UDT, so with unexpected findings, toxicology analyses
should be verified and/or repeated.
Brief cognitive-behavioral interventions have been shown
to reduce the risk of COT misuse in chronic pain patients.
Using a randomized trial, Jamison and colleagues [58]
Figure 1 Stratification of chronic pain patients by use of screening tools (cited in text) into high, medium, and low risk groups for
opioid abuse, monitoring patients by using urine dug screening (UDS), Prescription Monitoring Programs (PMPs) and aberrant
behaviors; and lastly establishing suggested dose (MED: Morphine Equivalent dose) limits. Adopted from [48].
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tive behavioral treatment (education and motivational
counseling) in patients at high risk for opioid misuse
(due to a past history of addiction) in a pain manage-
ment center. They found that no participant receiving
cognitive-behavioral treatment was discharged due to
aberrant behaviors, and that opioid treatment adherence
and opioid misuse behaviors were better in this group
than in those who did not receive the enriched treatment.
Identification of addiction in the chronic pain patient
receiving COT
Savage and colleagues introduced the four “C” criteria for
identifying opioid addiction in chronic pain population:
impaired control over drug use, compulsive use, continued
use despite harm, and unmanageable drug craving [10].
However, these criteria have not been validated in clinicalsettings. The multiple screening and assessment tools pre-
viously identified are helpful in identification, especially if
compared with scores upon admission.
A strategy to distinguish between aberrant or misuse
behaviors and addiction in chronic pain patients is to
assess the relationship between opioid dose titration
and functional restoration (Figure 2). In this approach,
in response to aberrant “drug-seeking” behaviors (ie,
continued complaints of pain and/or requests for more
medication), the clinician increases the opioid dose in
an effort to provide analgesia. Improvements in func-
tional outcomes and quality of life, with fewer problem-
atic behaviors, indicate that active addiction is not
present. In this case, drug-seeking behaviors may reflect
pseudo-addiction, therapeutic dependence, or opioid
tolerance (Table 1). Effective dosing results in functional
restoration.
Figure 2 Decision tree for interpreting aberrant prescription opioid use behavior in the chronic pain patients on opioid therapy.
Adapted from [59,60].
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a dose increase, addiction is considered in the differential
diagnosis. Listed in Figure 2 are alternate explanations
for poor functional improvement, including non-opioid
responsive pain; opioid-induced hyperalgesia; or an un-
treated psychiatric disorder. In these circumstances,
clinicians should consider taper of the opioid dose
and replace it with other pain-relief strategies [61] to
improve function and quality of life. If the patient shows
resistance to detoxification and cannot comply with the
alternative treatment plan, addiction should be considered.Treating chronic pain in SUD patients receiving COT
Patients with untreated addiction: focus on addiction
treatment
The authors strongly believe that patients with chronic pain
and active addiction, regardless of type(s) of substance
abused, are not candidates for COT [62]. Patients meeting
DSM-V criteria for addiction and related disorders are, by
definition, unable to achieve the goals of functionalrestoration. Untreated addiction results in poor functiona-
lity and, thus, will necessarily result in poor pain outcomes.
In many primary care or pain management settings,
the ability to provide the comprehensive services neces-
sary to treat patients with both pain and current addic-
tion are sorely lacking. Patients with an active SUD
should be referred to formal addiction treatment; thus,
it is incumbent upon the prescribing clinician to have
available a referral network of substance abuse treat-
ment providers willing to collaborate on providing care
to patients with comorbid pain and SUD. After referral,
the pain clinician should continue to work closely with
the SUD treatment provider to monitor use behaviors
and pain outcomes.Patients with addiction in remission: focus on relapse
prevention
For individuals with addiction in remission, the goal of
treatment is the same as that as for all chronic pain
patients: to improve pain and maintain functionality.
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patient’s ability to comply with regimens; engage in
cognitive-behavioral pain management strategies; utilize
positive coping skills to manage stress; and establish better
social support systems. Further, management of comorbid
neuropsychiatric complications is critical to maximize
functionality.
For many opioid addicts, disease remission includes
opioid substitution therapy. In the context of managing
pain in patients receiving methadone or buprenorphine
for addiction, it is commonly assumed that the treatment
opioid alone provides sufficient pain relief. Further, con-
cerns that additional opioids put the patient at risk for
untoward events, including respiratory depression and
decreased level of consciousness [63], often limit opioid
prescription. Although methadone and buprenorphine
can be used to treat pain, their duration of analgesic ac-
tion is shorter than effects on withdrawal and craving,
thus dividing the daily dose and giving more frequently
is the indicated strategy [64,65]. Further, patients on
opioid substitution therapy develop some degree of opi-
oid analgesic tolerance, and thus may require higher
opioid doses to appreciate pain relief [40,66,67]. Studies
have provided evidence that methadone maintenance
patients may, in fact, have heightened pain sensitivity,
and therefore have a higher opioid analgesic require-
ment than matched controls [68].
Regardless of the type(s) of substance previously abused,
exposure to psychoactive medications can lead to relapse
in patients with a recently or poorly treated SUD. Con-
cerns of relapse may also contribute to clinicians’ reluc-
tance to prescribe COT for patients whose addiction is
in remission. The literature provides evidence thatFigure 3 The cognitive-behavioral model of the relapse process posit
coping response to those situations. People with effective coping respo
probability of a relapse. Conversely, people with ineffective coping respons
drug use will have a positive effect (i.e., positive outcome expectancies), ca
guilt and failure (i.e., an abstinence violation effect). The abstinence violatio
probability of a relapse. Adopted from [75].patients with successfully treated addiction can be ef-
fectively treated with opioids for chronic pain [69].
Thus, when providing COT to these patients, in
addition to maximizing functionality, the treatment
goals include preventing an exacerbation of the SUD.
Central to this treatment is the integration of relapse
prevention strategies into the plan of care. Relapse is a
predictable event in the course of addictive disease and is
understood to be a process that does not occur suddenly
or spontaneously and is, therefore, preventable [70,71].
The well-known social-psychology model of relapse intro-
duced by Marlatt and Gordon [72] almost 30 years ago
suggests that relapse is part of the behavioral change
process and relatively common as the patient attempts to
integrate new and healthier self-management behaviors
into his or her life. Substance use disorders are chronic
diseases for which significant behavioral change is
required to successfully achieve remission.
The relapse prevention model is depicted in Figure 3.
A basic assumption of the model is that relapse events
are preceded by encountering a high-risk situation, broadly
defined as “a circumstance in which an individual’s at-
tempt to refrain from a particular behavior (ranging from
any use of a substance to heavy or harmful use) is threat-
ened” (p. 224) [73]. For patients with a history of SUD,
triggers for relapse are attributed to both intrapersonal
and interpersonal stressors. For patients with chronic pain,
unique stressors include the losses and limitations associ-
ated with chronic pain and pain-related diminished quality
of life. Although some high-risk situations (eg, negative
affect, craving) seem to be universal across addictive be-
haviors, they vary across individuals and may change
within the same individual over time [74].s a central role for high-risk situations and for the SUD patient’s
nses to high-risk situations (i.e., increased self-efficacy), are at decreased
es (decreased self-efficacy) which, together with the expectation that
n result in an initial lapse. This lapse, in turn, can result in feelings of
n effect, along with positive outcome expectancies, can increase the
Table 4 Questions to assess risk for relapse
• How long has patient been in recovery?
• How engaged is the patient in addiction recovery efforts/treatment
(i.e., supportive counseling, 12-step program)?
• What type(s) of drugs were abused?
• What are current stressors that might precipitate relapse? These
include unrelieved pain; sleep disorders; withdrawal symptoms;
psychiatric symptoms, interpersonal conflicts.
• What are current protective factors against relapse, including
improved coping responses and a social support system?
• How stable does patient feel in recovery?
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is determined by the individual's ability to engage an
effective coping response to the stressor [71]. In the
model, positive outcome expectancies and the abstinence
violation effect are important cognitive factors in deter-
mining relapse probability. Positive-outcome expectancies
refer to the anticipated positive effects of substance use
(eg, getting “high,” decreasing anxiety, social rewards),
which override memories of the consequences associated
with use. The abstinence violation effect refers to the
patient viewing a single lapse, or “slip,” as a personal
failure, leading to feelings of guilt, demoralization,
and hopelessness with respect to his or her ability to
maintain change. More recent conceptualizations of
relapse describe it as a dynamic phenomenon, and a
complex nonlinear process in which various factors
act jointly and interactively to influence relapse timing
and severity [73].
Central to successful relapse prevention are learned
cognitive and behavioral strategies the patient can employ
in the face of high-risk situations. These strategies are of
two broad categories: (1) a specific intervention technique
designed to assist the individual in anticipating and ef-
fectively coping with high-risk situations; and (2) global
self-control approaches designed to reduce relapse risk
by promoting positive lifestyle changes. In that high-
risk situations vary among individuals, it is critical to
conduct a comprehensive assessment of substance use
patterns, high-risk situations, coping skills, self-efficacy,
outcome expectancies, and readiness to change, as well
as to document coexisting conditions that may compli-
cate the relapse-prevention process. To increase insight
into, and self-monitoring of, problematic behaviors, the
patient is encouraged to identify immediate precipitants
and distal lifestyle factors related to relapse and to
evaluate his or her own coping responses to high-risk
situations.
Specific intervention strategies include enhancing
self-efficacy by setting achievable behavioral goals and
purposeful dispelling of positive outcome expectancies.
With respect to global self-control strategies, patients
are encouraged to incorporate stress-reduction acti-
vities into their daily life, such as exercise or meditation.
The overall purpose is lifestyle balancing, which in-
creases self-efficacy across life domains and therefore
minimizes the risk of relapse.
Relapse-prevention strategies for SUD patients receiving
COT
Preventing relapse is central to effective COT in patients
with SUD in remission. Clinicians must continuously
assess the patient’s relative risk for it and monitor for its
emergence. Further, the ability to manage a relapse epi-
sode, if one should occur, is a necessary skill of the COTprescriber. With addiction in remission, optimal function-
ing with appropriate opioid use can be appreciated.
Assessment of risk of relapse
A series of questions should be asked of the chronic pain
patient regarding the status of SUD remission (Table 4).
Asking these questions at each visit allows for early
identification of high-risk situations and potential cop-
ing responses to these stressors.
Recognition of and monitoring for relapse
The identification of relapse in chronic pain patients
receiving COT is complicated by their tendency to hide
problematic use for the fear of losing access to medica-
tions. A careful monitoring plan including general and
additional precautions (as described above) is critical. A
relapse contract can be developed with the patient in
early treatment, which is individualized to the patient
and specifies steps or actions that will be taken by both
the patient and clinician if relapse occurs. The patient’s
behaviors with respect to the opioid-analgesic regimen
provide the best evidence for the presence of active ad-
diction. Evidence of relapse in chronic pain patients in-
cludes the presence of adverse consequences associated
with opioid use, a loss of control over the use of opioids,
preoccupation with obtaining opioids, and a lack of
improvement in function [10].
An objective indicator of medication use is adher-
ence to a treatment contract or medication agreement,
which clearly outlines acceptable and unacceptable
medication use behaviors. However, engaging in un-
acceptable medication-taking behaviors cannot be con-
sidered a definitive indicator of addictive disease, and
rather may reflect an untreated psychiatric disorder or
misunderstanding of dosing instructions. Similarly,
unexpected UDT results may indicate patients’ non-
adherence to opioid regimen or problematic use of
medications, but it is not a specific indicator of re-
lapse to addictive disease. Thus, clinicians should not
summarily discharge SUD patients from COT based on
behavioral indicators or UTD results; neither are specific
to exacerbation of addiction. Rather, these findings should
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tients with a history of SUD who are nonadherent to the
prescribed opioid regimen should be strongly encouraged
to increase recovery efforts, and their access to opioids
should be more tightly controlled. Evaluation by an addic-
tion specialist is warranted if behaviors do not quickly
resolve.
Management of relapse
If relapse is identified, it is critical to continue to support
patients’ efforts towards recovery and maintain high levels
of controls over opioid access. If attempted, opioid de-
toxification should be gradual so as not to elicit opioid
withdrawal symptoms (usually, no more than a 20-25%
dose reduction every two days). It is important not to
characterize the relapse as a treatment failure but to
frame it as a part of the process of recovery from an
addictive disease and successful pain treatment.
Studies indicate that exposure to specific high-risk
situations alone does not predict relapse, but the way in
which people cope with those situations is a strong pre-
dictor of subsequent relapse or continued abstinence
[76-78]. Following a relapse, a careful review of the
relapse episode can be helpful. This analysis should
chronicle the relapse and identify associated emotional
and cognitive status that preceded it. Doing so will help
the patient better recognize his/her own vulnerability
to relapse as well as coping strategies that may or may
not be effective.
If relapse is identified, discharging the patient from
pain treatment without providing addiction intervention
is not only premature, but sets the patient up for the
progression of addictive disease. It is important that
clinicians who prescribe COT for chronic pain are
prepared with a relapse management strategy and have
addiction expertise or support in place. It is critical
that COT providers maintain a thoughtful and working
partnership with addiction treatment providers so that
pain treatment can continue while supporting addiction
remission. As opposed to discharge, it is incumbent upon
the pain-management practitioner to take more of an
advocacy role in the management of addiction.
Conclusion
Management of chronic pain in patients with a history
of SUD with COT can be challenging, but with appro-
priate assessment and management, can be successful,
leading to enhanced functionality and quality of life. Al-
beit imperfect, data suggest that up to one-quarter of
chronic pain patients have an SUD history. The inter-
related behavioral symptomatology of addiction and
chronic pain suggests that the untreated presence of one
precludes effective treatment of the other. Demographic
correlates and risk factors for SUD have been well-described, and COT management is most successful when
based upon risk stratification with increased control of
opioid access for those classified as high risk.
The evidence is good that COT can be effective in pa-
tients with chronic pain whose SUD is in remission,
suggesting that a primary goal of treatment, in addition
to improving pain and maximizing functionality, is to
prevent a relapse or exacerbation of addictive disease.
Expanding the pain treatment plan to include specific
relapse-prevention strategies and directed relapse man-
agement, if needed, is critical to appreciate the benefits
of COT for patients with a history of SUD. Identifying
relapse in this population can be challenging and should
not be based on a single indicator. Premature discharge
of the SUD patient from pain treatment provides an
opportunity for addiction to worsen. It is suggested that
the best chronic pain outcomes occur when the pain
clinician and addiction treatment provider work in
concert using a syndromal approach to treat pain and
addiction.
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